- Home
- JZ vs APVO Comparison
JZ vs APVO Comparison
Compare JZ & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZ
- APVO
- Stock Information
- Founded
- JZ 2011
- APVO 2016
- Country
- JZ China
- APVO United States
- Employees
- JZ N/A
- APVO N/A
- Industry
- JZ Other Consumer Services
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- JZ Real Estate
- APVO Health Care
- Exchange
- JZ Nasdaq
- APVO Nasdaq
- Market Cap
- JZ 4.9M
- APVO 4.9M
- IPO Year
- JZ 2022
- APVO N/A
- Fundamental
- Price
- JZ $1.64
- APVO $1.78
- Analyst Decision
- JZ
- APVO
- Analyst Count
- JZ 0
- APVO 0
- Target Price
- JZ N/A
- APVO N/A
- AVG Volume (30 Days)
- JZ 22.6K
- APVO 16.3M
- Earning Date
- JZ 09-26-2025
- APVO 11-06-2025
- Dividend Yield
- JZ N/A
- APVO N/A
- EPS Growth
- JZ N/A
- APVO N/A
- EPS
- JZ N/A
- APVO N/A
- Revenue
- JZ $34,090,704.00
- APVO N/A
- Revenue This Year
- JZ N/A
- APVO N/A
- Revenue Next Year
- JZ N/A
- APVO N/A
- P/E Ratio
- JZ N/A
- APVO N/A
- Revenue Growth
- JZ N/A
- APVO N/A
- 52 Week Low
- JZ $1.30
- APVO $1.32
- 52 Week High
- JZ $14.60
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- JZ 47.59
- APVO 53.33
- Support Level
- JZ $1.62
- APVO $1.41
- Resistance Level
- JZ $1.83
- APVO $1.49
- Average True Range (ATR)
- JZ 0.11
- APVO 0.18
- MACD
- JZ -0.02
- APVO 0.04
- Stochastic Oscillator
- JZ 8.24
- APVO 35.04
About JZ Jianzhi Education Technology Group Company Limited
Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has two operating segments: Educational content services and other services and IT-related solution services.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.